PortalPublikationenAn open-label, phase I/II trial to determine the maximum tol...

An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia

  • Walter Fiedler
  • Pau Montesinos
  • Christoph Schliemann
  • Jan Middeke
  • Sumithira Vasu
  • Christian W Scholz
  • Jordi Esteve
  • Shoubhik Mondal
  • Björn Rüter
  • Ute Burkard
  • Annika Osswald
  • William Blum

Beteiligte Einrichtungen

Abstract

Not available.

Bibliografische Daten

OriginalspracheEnglisch
ISSN0390-6078
DOIs
StatusVeröffentlicht - 01.12.2022
PubMed 36005556